UPDATE: Alexion (ALXN) Peers Ramp
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Join SI Premium – FREE
(Updated - July 12, 2013 2:30 PM EDT)
Alexion (Nasdaq: ALXN) peers moved higher on rumors Roche was targeting the company. Gainers include BioMarin Pharma (Nasdaq: BMRN), Seattle Genetics (Nasaq: SGEN), and Vertex (Nasdaq: VRTX), InterMune Inc. (Nasdaq: ITMN), Immunomedics Inc. (Nasdaq: IMMU), Ariad Pharmaceuticals Inc. (Nasdaq: ARIA), and Pharmacyclics Inc. (Nasdaq: PCYC), Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN), among others.
Reports say Roche is seeking billions of dollars in financing for a potential takeover of Alexion, according to Bloomberg sources.
ProShares Ultra Nasdaq Biotechnology ETF (Nasdaq: BIB) jumped 4%.
Alexion (Nasdaq: ALXN) peers moved higher on rumors Roche was targeting the company. Gainers include BioMarin Pharma (Nasdaq: BMRN), Seattle Genetics (Nasaq: SGEN), and Vertex (Nasdaq: VRTX), InterMune Inc. (Nasdaq: ITMN), Immunomedics Inc. (Nasdaq: IMMU), Ariad Pharmaceuticals Inc. (Nasdaq: ARIA), and Pharmacyclics Inc. (Nasdaq: PCYC), Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN), among others.
Reports say Roche is seeking billions of dollars in financing for a potential takeover of Alexion, according to Bloomberg sources.
ProShares Ultra Nasdaq Biotechnology ETF (Nasdaq: BIB) jumped 4%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exclusive-US weighs polysilicon price floor, tariffs to counter China in solar and chips
- Bank of America favors high yield over investment grade bonds
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
Create E-mail Alert Related Categories
ETFs, General News, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
